Jordana Jampel

DocwireNews

Researchers conducted the coArtHA clinical trial, which aimed to determine (1) whether a two-pill antihypertensive strategy is noninferior and (2) whether a low-dose three-pill strategy is superior to full-dose monotherapy plus stepped escalation for controlling blood pressure in people with hypertension in rural Tanzania and Lesotho. Results were <a href="https://jamanetwork.com/journals/jamacardiology/fullarticle/2829432">published</a> in JAMA Cardiology.
The open-label, parallel, three-arm randomized study included 1,268 participants with confirmed, uncomplicated, untreated hypertension. Investigators used a superiority design for the comparison between starting a three-pill strategy (calcium channel blocker [CCB]/angiotensin II receptor blocker [ARB]/hydrochlorothiazide) and a stepped CCB monotherapy strategy (CCB/hydrochlorothiazide) and a noninferiority design for the comparison of starting a two-pill strategy (CCB/ARB).
Hypertension was determined by standardized blood pressure ≥140/90 mm Hg; exclusion criteria included blood pressure ≥180/100 mm Hg with acute headache or chest pain. Participants were randomly assigned 2:1:1 to stepped monotherapy (n=505), the two-pill strategy (n=510), or the three-pill strategy (n=253). The two-pill cohort started with amlodipine 5 mg and losartan 50 mg administered once daily; the three-pill cohort started with amlodipine 2.5 mg, hydrochlorothiazide 6.25 mg, and losartan 12.5 mg administered once daily with subsequent dose escalation in all groups if blood pressure was above target.
The primary endpoint was the proportion of participants reaching target blood pressure at 12 weeks. The blood pressure target was ≤130/80 mm Hg for participants younger than 65 years and ≤140/90 mm Hg for those aged 65 years or older.
In noninferiority analyses, 207 of 370 participants (56%) in the two-pill cohort and 173 of 338 participants (51%) in the monotherapy cohort achieved the blood pressure target (adjusted odds ratio [aOR], 1.18; 95% CI, 0.87-1.61), fulfilling noninferiority.
In superiority analyses after multiple imputation for missing outcome data, 57% of participants in the three-pill cohort, 55% in the two-pill cohort , and 49% in the monotherapy cohort reached the target blood pressure (aOR, 1.24; 95% CI, 0.94-1.63; P=.12 and aOR, 1.28; 95% CI, 0.91-1.79; P=.16 for the two-pill and three-pill vs stepped monotherapy strategies, respectively).
The researchers concluded that “wide CIs preclude the ability to rule out potentially clinically important effects of the additional pill strategies for hypertension control. Initial monotherapy with full-dose amlodipine led to a rapid blood pressure reduction at the cost of increased risk of adverse events, whereas the combination strategies might improve blood pressure control in those younger than 65 years targeting a lower blood pressure.”
Source
<a href="https://jamanetwork.com/journals/jamacardiology/fullarticle/2829432">JAMA Cardiology</a>

Laura Litwin

Preventing POAF: Partial Cardiac Denervation After CABG Reduces Incidence Without Increasing Complications

Atrial Fibrillation

Cecilia Brown

EMA CHMP Recommends Durvalumab for Limited-Stage SCLC

Small Cell Lung Cancer

New Discovery on Genomic Structure Change as Biomarker for Brain-Related Diseases

Stroke

Latest News

Two-Pill Versus Three-Pill Step Dosage Effectiveness Compared With Monotherapy for Hypertension

Hypertension

Researchers aimed to determine whether a two-pill antihypertensive strategy is effective at controlling hypertension.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Heart Failure

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe